Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche - LARVOL DELTA

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. (PubMed, N Engl J Med) - P3 | "Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP. (Funded by F. Hoffmann-La Roche/Genentech; POLARIX ClinicalTrials.gov number, NCT03274492.)."

Journal • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD79B

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network (ASH 2024) - "In the context of ibrutinib- and high-dose cytarabine-containing induction immuno-chemotherapy and ibrutinib maintenance, the addition of ASCT failed to show FFS superiority, while increasing toxicity during maintenance/follow-up. According to the pre-defined decision strategy, ibrutinib+R-CHOP/R-DHAP induction followed by 2 years of ibrutinib maintenance should be the new standard of care in younger MCL patients, thus ending the era of ASCT for MCL patients."

Clinical • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • Transplantation

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. (PubMed, Blood) - P1/2 | "Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Epcoritamab + GemOx yielded deep, durable responses and favorable long-term outcomes in ASCT‑ineligible R/R DLBCL. NCT04663347."

Journal • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. (PubMed, Lancet) - P3 | "Glofit-GemOx had a significant overall survival benefit compared with R-GemOx, supporting its use in transplant-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma after one or more previous lines of therapy."

Clinical • Journal • P3 data • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA-R-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE RANDOMIZED PHASE III POLARGO TRIAL (EHA 2025) - P3 | "Background: Polatuzumab vedotin is approved in frontline and R/R DLBCL, with the latter involving a combination with bendamustine and rituximab (Tilly H, et al. This study met its primary and all key secondary endpoints. Pola-R-GemOx demonstrated a statistically significant and clinically meaningful benefit in OS and PFS, with a 40% reduction in risk of death relative to R-GemOx. Pola-R-GemOx was associated with known risks of individual components, including PN and infection, but neither significantly impacted study endpoints."

Clinical • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Thrombocytopenia

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. (PubMed, J Clin Oncol) - P3 | "Mosun-Pola demonstrated superior efficacy verus R-GemOx, with significant improvements in both overall response rate and progression-free survival, and infrequent cytokine release syndrome events with a manageable safety profile.(Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT05171647)."

Journal • P3 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma (ASH 2025) - "For this reason, we developed R‑Pola‑Glo, comprising the CD20 antibodyrituximab (R), the antibody‑drug conjugate polatuzumab vedotin (anti‑CD79B; Pola), and the bispecificantibody glofitamab (CD20×CD3; Glo)...Cycle 1 included obinutuzumab, Pola, and step‑up Glo (2.5/10 mg); cycles 2‑6 combined R, Pola,and Glo at 30 mg; cycles 7‑12 consisted of Glo consolidation (30 mg)...Exploratory subgroup analysis suggested that R‑Pola‑Glo efficacy was consistent across allsGA risk groups and mitigated the adverse prognostic impact of classical IPI factors, including LDH.ConclusionsR-Pola-Glo achieved high and durable CMR rates with an expected and manageable safety profile,translating into favorable 1-year survival rates in elderly/frail and medically unfit patients with aggressiveB-cell lymphoma. Compared with other regimens for this population, R‑Pola‑Glo demonstrated higherresponse rates and improved survival outcomes at 1 year, strongly supporting its further..."

Clinical • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Geriatric Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Respiratory Syncytial Virus Infections • CD79B

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. (PubMed, Blood Adv) - P3 | "In the phase 3 STARGLO trial (NCT04408638), glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) demonstrated superior overall survival (OS) vs rituximab (R)-GemOx, in patients with autologous stem cell transplant (ASCT)-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). With extended follow-up, fixed-duration Glofit-GemOx continues to demonstrate superior survival vs R-GemOx in ASCT-ineligible patients with R/R DLBCL, with favorable outcomes pronounced in the 2L setting, and consistent across subgroups including elderly and early relapsing patients. These data support Glofit-GemOx as an effective off-the-shelf treatment with curative potential in R/R DLBCL."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma. (PubMed, Blood Adv) - P3 | "R2 showed a more favorable benefit/risk profile in patients <70 years whereas in older patients careful consideration of individual tolerability is warranted. Trial registration: RENOIR study (NCT02390869) clinicaltrial.gov."

Journal • P3 data • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology

Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort. (PubMed, Hematol Oncol) - P=N/A | "Older patients were treated with bendamustine-rituximab (28%), R-CHOP (18%), and low-dose cytarabine (20%)...In the second-line setting (n = 72), most patients were POD24 (89%) and 56% received ibrutinib, yet outcomes remained poor (CR 24%, ORR 35%, median EFS and OS of 6.3 and 25.6 months, respectively). These findings underscore the need for improved strategies for older and high-risk patients. Retrospective landmark analyses suggest a potential association between RM and improved EFS but are limited by baseline differences between groups."

Journal • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

MorningLyte: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (clinicaltrials.gov) - P3 | N=790 | Active, not recruiting | Sponsor: The Lymphoma Academic Research Organisation | Recruiting ➔ Active, not recruiting

Enrollment closed • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: Weill Medical College of Cornell University | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2026 ➔ Jan 2027

Enrollment closed • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Richter's Syndrome

Orelabrutinib plus Rituximab Maintenance after Short-Course Chemoimmunotherapy in Intermediate/High-Risk Marginal Zone Lymphoma (ESMO 2026) - No abstract available

Clinical • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology

Clinical Outcomes of Reduced-Dose Whole-Brain Radiotherapy After Induction Chemotherapy for Primary Central Nervous System Lymphoma: A Retrospective Single-Institution Study (ASTRO 2026) - "Induction chemotherapy consisted of R-MPV (rituximab, methotrexate, procarbazine, and vincristine) up to seven cycles, followed by two cycles of high-dose cytarabine administered as consolidation after radiotherapy. Reduced-dose WBRT following induction chemotherapy provided durable disease control and favorable survival outcomes in a real-world PCNSL cohort. These findings support rdWBRT as an effective consolidative strategy. Further investigation of neurocognitive outcomes is warranted."

Clinical data • Retrospective data • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Response-Directed Radiotherapy after Methotrexate-Based Systemic Therapy for Patients with Primary CNS Lymphoma (ASTRO 2026) - "The most common ST regimen was HD-MTX, Procarbazine, and Vincristine (MPV) +/- Rituximab (R) in 32/52 (62%) of pts, while 13/52 (25%) received HD-MTX +/- R, and 7/52 (13%) received other HD-MTX-based regimens. 16/52 pts (31%) received consolidative cytarabine... In pts with PCNSL treated with HD-MTX-based ST, an RT approach incorporating a boost to residual disease is associated with improved PFS. Further investigation into optimal consolidative strategies in pts with a PR following HD-MTX-based induction is warranted."

Clinical • CNS Lymphoma • Eye Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Primary Vitreoretinal Lymphoma • Secondary Central Nervous System Lymphoma

Risk-Adapted Consolidative Radiotherapy in Rituximab-Treated Diffuse Large B-Cell Lymphoma: A Single-Institution Cohort (ASTRO 2026) - "In rituximab-treated DLBCL, consolidative RT was associated with fewer relapses and improved RFS, with the clearest signal in limited-stage disease and among complete responders. The attenuation after adjustment highlights potential selection bias and supports validation using prospective or propensity-adjusted analyses to refine RT selection."

Clinical • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Lipid Homeostasis Targeting via ABCA1 Preserves Normal Tissue Function and Enhances Tumor Response After Radiation (ASTRO 2026) - "Cells were treated with radiation (6 Gy) with or without cisplatin (40 µM administered 24 h before irradiation) in the presence or absence of lipid-modulating therapies, including rituximab (10 µg/mL, 24 h pre-irradiation), the LXR agonist GW3965 (5 µM), or methyl-ß-cyclodextrin (1 mM). Radiation-induced disruption of lipid homeostasis represents a key mechanism underlying normal tissue injury. Pharmacologic restoration of ABCA1-dependent cholesterol efflux selectively protects normal tissues while maintaining or enhancing tumor response. Targeting lipid metabolism, therefore, represents a clinically translatable strategy to expand the therapeutic index of chemoradiotherapy and improve long-term survivorship outcomes."

Oncology • ABCA1

30Gy vs 40Gy Consolidative Radiotherapy for Limited-Stage Diffuse Large B cell Lymphoma Achieving Complete Remission after Chemotherapy: A Randomized, Open-Label, Non-Inferiority, Multicenter Phase 3 Clinical Trial (ASTRO 2026) - "Materials/ In this multicenter, non-inferiority, open-label, phase 3 trial, patients aged =15 years with newly diagnosed stage I-II DLBCL who achieved complete response (CR)/CRu after anthracycline-based chemotherapy with/without rituximab were randomly assigned (1:1) to 30 Gy or 40 Gy involved-site/field RT... For patients with limited-stage DLBCL who achieve CR after chemotherapy, consolidative RT at 30 Gy provides non-inferior PFS compared with 40 Gy, with similar survival outcomes and toxicity profiles. These findings establish 30 Gy as a new standard of care in this setting, enabling reduced treatment intensity and potential long-term toxicity without compromising disease control."

Clinical • Head-to-Head • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Results of the Phase II POLARIS Study (ESMO 2026) - No abstract available

P2 data • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

Accelerated rituximab infusion up to 15 minutes in haematological malignancies: a prospective pilot study (ESMO 2026) - No abstract available

Clinical • Hematological Malignancies • Oncology

First Report of a Phase Ib Study of Rocbrutinib, a Fourth-Generation Bruton's Tyrosine Kinase Inhibitor, Combined with R-CHOP in Patients with Previously Untreated B-Cell Lymphoma (ESMO 2026) - No abstract available

Clinical • P1 data • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Gastrointestinal Involvement of Untreated Follicular Lymphoma Presenting With Partial Small Bowel Obstruction (ACG 2026) - "Rituximab therapy was initiated by oncology with significant improvement in symptoms...Al-assisted language editing was used in the preparation of this abstract. Figure: Enteroscopy findings of whitish villi in the duodenum."

IO biomarker • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2 • CCND1 • CD20 • CD5 • CD79A • MME

A Very Rarely Reported Case of Multifocal Intestinal Diffuse Large B-Cell Non-Hodgkinâs Lymphoma Presenting as a Concurrent Small and Large Bowel Obstruction (ACG 2026) - "For patients presenting with bowel obstruction due to DLBCL, treatment typically involves surgical resection followed most commonly by the R-CHOP chemotherapy regimen, consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Figure: Image 1. CT abdomen/pelvis showing a mass involving the small bowel loop within the right mid abdomen measuring 9.7 x 5.6 cm, as well as a lesion surrounding the hepatic flexure measuring 6.3 x 7.5 cm."

Clinical • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Small Intestinal Carcinoma • BCL2

An Unusual Case of an Enterocolonic Fistula Associated With PTLD Following Double Lung Transplantation (ACG 2026) - "Therefore, inpatient treatment with rituximab, cyclophosphamide, doxorubicin, and prednisone (modified split-dose R-CHOP) was initiated. This led to the patient receiving an expedited diagnosis and thus more timely initiation of therapy. Figure: Ulcerated Lesion located at 4th portion of duodenum Figure: Enterocolonic fistula connecting the small bowel (blue arrow) and colon (yellow arrow)."

Clinical • Bronchopulmonary Dysplasia • Gastrointestinal Disorder • Pulmonary Disease • Respiratory Diseases • Transplantation

That Escalated Quickly: A Primary Duodenal Follicular Lymphoma Masked as Chronic Dyspepsia (ACG 2026) - "Management options include watchful waiting given its indolent and localized nature, rituximab monotherapy, and radiotherapy...This case reinforces the value of endoscopic vigilance and multidisciplinary collaboration in managing a rare but treatable disease. Figure: Endoscopy images of the duodenum"

B Cell Lymphoma • Dyspepsia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma